Last reviewed · How we verify
Lamivudine Abacavir Raltegravir
Lamivudine Abacavir Raltegravir is a Small molecule drug developed by Catholic University of the Sacred Heart. It is currently in Phase 2 development.
At a glance
| Generic name | Lamivudine Abacavir Raltegravir |
|---|---|
| Sponsor | Catholic University of the Sacred Heart |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Blood cholesterol increased
- Blood sodium decreased
- Low density lipoprotein increased
- Diarrhoea
- Upper respiratory tract infection
- Blood bicarbonate decreased
- Blood phosphorus decreased
- Headache
- Aspartate aminotransferase increased
- Blood alkaline phosphatase increased
- Nausea
- Neutrophil count decreased
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed (PHASE2)
- Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients (PHASE4)
- Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lamivudine Abacavir Raltegravir CI brief — competitive landscape report
- Lamivudine Abacavir Raltegravir updates RSS · CI watch RSS
- Catholic University of the Sacred Heart portfolio CI
Frequently asked questions about Lamivudine Abacavir Raltegravir
What is Lamivudine Abacavir Raltegravir?
Lamivudine Abacavir Raltegravir is a Small molecule drug developed by Catholic University of the Sacred Heart.
Who makes Lamivudine Abacavir Raltegravir?
Lamivudine Abacavir Raltegravir is developed by Catholic University of the Sacred Heart (see full Catholic University of the Sacred Heart pipeline at /company/catholic-university-of-the-sacred-heart).
What development phase is Lamivudine Abacavir Raltegravir in?
Lamivudine Abacavir Raltegravir is in Phase 2.
What are the side effects of Lamivudine Abacavir Raltegravir?
Common side effects of Lamivudine Abacavir Raltegravir include Blood cholesterol increased, Blood sodium decreased, Low density lipoprotein increased, Diarrhoea, Upper respiratory tract infection, Blood bicarbonate decreased.